查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1837443

口服疫苗市场（按疫苗类型、适应症、年龄层和分销管道划分）—2025-2032 年全球预测

Oral Vaccine Market by Vaccine Type, Disease Indication, Age Group, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年口服疫苗市场规模将成长至 300.6 亿美元，复合年增长率为 6.68%。

主要市场统计数据
基准年2024年 179.1亿美元
预计2025年 190.9亿美元
预测年份：2032年 300.6亿美元
复合年增长率（%） 6.68%

全面介绍口服疫苗的创新、公共卫生相关性、科学进步以及全球策略和商业性影响

口服疫苗已成为预防医学领域不断发展的关键工具，在给药、分发和患者接受度方面具有显着优势。过去十年，製剂科学、黏膜免疫学和给药技术的进步汇聚在一起，重新激发了研发人员和公共卫生官员的兴趣。这些创新旨在减少针头疫苗接种的障碍，提高疫苗的耐热性以减少低温运输黏膜免疫反应更有效地阻断病原体传播。

随着相关人员重新评估免疫策略，口服疫苗提案不仅提供了便利，还可能提高供应链效率并降低管理成本。在临床上，口服疫苗接种有助于开展针对缺乏训练有素的医护人员地区的大规模疫苗宣传活动和项目，从而实现公平目标。同时，科学界正在不断改进抗原呈现、佐剂选择和载体设计，以提高包括儿童和老年人群在内的不同人群的免疫抗原性。

本导言旨在对口服疫苗开发和商业化的驱动因素、障碍和策略考量进行细緻的探讨。它强调了科学创新、监管趋势和分销模式之间的相互作用，这些因素共同决定了口服疫苗从有希望的候选疫苗转变为全球免疫计划常规组成部分的速度。本导言旨在提供一个平衡的基准，随后的章节重点关注不断变化的情况、贸易影响、细分动态、区域差异、企业策略以及对整个生态系统领导者的实用建议。

分析正在重新定义口服疫苗开发和交付范式的变革性科学、监管、分销和患者主导的转变

在技​​术突破、相关人员期望变化和法律规范不断演变的推动下，疫苗领域正在经历一场变革性的转变。在科学层面，mRNA平台、载体设计和抗原稳定性的进步，使得以往难以实现的口服给药方式成为可能。此外，製剂科学的改进也为这些进步提供了补充，这些改进可以保护不稳定分子免受胃肠道降解，并靶向诱导粘膜免疫。因此，研发重点日益集中在持续的黏膜免疫、节省剂量的策略和便捷的给药方式。

同时，公共卫生重点正转向建构具有韧性的免疫系统，以应对地方性和突发性威胁。这种对韧性的关注有利于简化物流的方法，例如无针给药和低温运输要求较低的製剂。监管机构正在不断改进其指导方针，以适应新的给药技术，并为衔接临床试验和真实世界证据生成创建更清晰的途径。私营部门投资者和策略合作伙伴正在透过重新平衡其投资组合来应对，将早期口服候选药物和扩充性的平台技术纳入其中。

此外，终端用户的期望和医疗保健服务模式正在重塑商业性模式。患者和看护者越来越重视便利性和微创性，这推动了口服疫苗在社区和门诊的普及。数位医疗工具和远端医疗也透过实现疫苗接种计画、依从性追踪和远端监控，影响疫苗的配送。这些转变共同创造了一个充满活力的竞争环境，将科学可行性、监管清晰度、以患者为中心的设计和分销创新有机结合，加速口服疫苗概念转化为实践。

评估 2025 年美国关税如何重塑供应链策略、采购动态和製造在地化

美国2025年实施的关税政策变化的累积效应，为疫苗开发商、製造商和采购实体带来了新的考量。这些贸易措施虽然与更广泛的产业战略目标一致，但也影响到疫苗价值链中的多个环节，包括原料药、辅料、专用包装材料以及灌装和表面处理工程所用设备的采购。因此，拥有全球分散式供应链的公司必须重新评估筹资策略和成本结构，以降低进口关税上调和港口处理延误带来的风险。

从实际角度来看，这项政策转变正在加速围绕供应链在地化、双重采购以及关键投入品策略性储备的讨论。製造商正在探索近岸外包选项，并扩大与国内合约研发和製造外包合作伙伴的关係，以缓解关税相关的脆弱性。这些变化也影响供应商合约谈判的动态，更重视价格透明度、运费优化和风险共用协议。采购团队越来越多地模拟关税对其营运的下游影响，包括前置作业时间和存货周转的变化，以保持临床项目和疫苗宣传活动的供应连续性。

对于官方采购商和贷款机构而言，关税导致预算和采购时间表更加复杂，从而重新燃起人们对长期供应协议的兴趣，并鼓励在关税优惠管辖区内进行製造业投资。重要的是，政策环境鼓励跨部门合作，以平衡国家战略目标与全球卫生需求，包括开展多边对话，以确保关税措施不会妨碍获得救命疫苗。展望未来，疫苗产业正在透过一系列营运韧性措施、策略伙伴关係和有针对性的资本投资进行调整，旨在保持专案的连续性，同时应对不断变化的贸易现实。

整合疫苗平台类型、目标疾病、人口需求和分销管道的关键细分洞察，为开发和商业化选择提供参考

了解市场需要从产品、临床、人口统计和分销等维度建立系统视角，每个维度都决定了开发重点和商业性方法。基于疫苗类型的市场分析考虑了结合疫苗、灭活疫苗、减毒疫苗、mRNA疫苗和次单位疫苗，并认识到每种平台都存在配方挑战和适合口服的免疫学特性。这些差异会影响关于抗原稳定性、给药方案以及保护性辅料和递送载体选择的决策。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 增加益生菌口服疫苗製剂的投资，以增强黏膜免疫
  • 监管部门的核准加速了新兴市场低温运输口服疫苗的开发
  • 采用可食用植物口服疫苗，降低生产成本，提高病患遵从性
  • 奈米技术载体在口服疫苗平台中靶向递送抗原的整合
  • 口服脊髓灰质炎疫苗根除宣传活动在策略性国际伙伴关係和资金支持下扩展

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章口服疫苗市场（依疫苗类型）

  • 结合疫苗
  • 灭活疫苗
  • 减毒活疫苗
  • mRNA疫苗
  • 次单位疫苗

9. 口服疫苗市场（依疾病适应症）

  • 流感
  • 诺罗病毒
  • 脊髓灰质炎
  • 轮状病毒

第 10 章口服疫苗市场（依年龄层）

  • 成人
  • 老年人
  • 孩子们

第 11 章口服疫苗市场（依通路）

  • 医院和诊所
  • 网路药局
  • 药局

第十二章口服疫苗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章口服疫苗市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 口服疫苗市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • AstraZeneca plc
    • Bharat Biotech International Limited
    • Emergent BioSolutions Inc.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Moderna, Inc
    • PT Bio Farma（Persero）
    • Sanofi SA
    • Sinovac Biotech Ltd
    • Valneva SE
Product Code: MRR-035DA3C63714

The Oral Vaccine Market is projected to grow by USD 30.06 billion at a CAGR of 6.68% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 17.91 billion
Estimated Year [2025] USD 19.09 billion
Forecast Year [2032] USD 30.06 billion
CAGR (%) 6.68%

Comprehensive introduction framing oral vaccine innovation, public health relevance, scientific advancements, and strategic commercial implications worldwide

Oral vaccines are emerging as a pivotal modality in the evolving landscape of preventive medicine, offering distinct advantages across administration, distribution, and patient acceptance. Over the past decade, advances in formulation science, mucosal immunology, and delivery technologies have converged to renew interest from developers and public health authorities alike. These innovations seek to reduce barriers associated with needle-based vaccination, improve thermostability to ease cold chain burdens, and exploit mucosal immune responses to interrupt pathogen transmission more effectively.

As stakeholders reassess immunization strategies, the oral vaccine proposition extends beyond convenience to encompass supply chain efficiencies and potential cost reductions in administration. In clinical contexts, oral delivery can facilitate mass immunization campaigns and targeted programs where trained personnel are scarce, thereby supporting equity goals. Concurrently, the scientific community continues to refine antigen presentation, adjuvant selection, and vector design to enhance immunogenicity across demographic groups, including pediatric and geriatric populations.

This introduction sets the stage for a nuanced examination of the drivers, barriers, and strategic considerations shaping oral vaccine development and commercialization. It emphasizes the interplay between scientific innovation, regulatory pathways, and distribution models, which collectively determine the pace at which oral vaccines transition from promising candidates to routine components of global immunization programs. The aim is to provide a balanced baseline that informs subsequent sections focused on landscape shifts, trade implications, segmentation dynamics, regional variations, corporate strategies, and pragmatic recommendations for leaders across the ecosystem.

Analysis of the transformative scientific, regulatory, distributional, and patient-driven shifts redefining the oral vaccine development and delivery paradigm

The vaccine landscape is undergoing transformative shifts driven by technological breakthroughs, altered stakeholder expectations, and evolving regulatory frameworks. At the scientific level, progress in mRNA platforms, vector design, and antigen stabilization is enabling new approaches to oral delivery that were previously impractical. These advances are complemented by improvements in formulation science that protect labile molecules from gastrointestinal degradation and target mucosal immune induction. As a result, development priorities are increasingly centered on durable mucosal immunity, dose-sparing strategies, and simplified administration.

Concurrently, public health priorities have shifted toward resilient immunization systems that can respond to both endemic pathogens and emergent threats. This focus on resilience favors modalities that simplify logistics, such as needle-free administration and formulations with relaxed cold chain requirements. Regulatory agencies are evolving their guidance to accommodate novel delivery technologies, creating clearer pathways for bridging trials and real-world evidence generation. Private sector investors and strategic partners are responding by rebalancing portfolios to include early-stage oral candidates and platform technologies that promise scalability.

Moreover, end-user expectations and healthcare delivery models are reshaping commercial approaches. Patients and caregivers increasingly prioritize convenience and minimal invasiveness, which supports the adoption of oral vaccines in community and outpatient settings. Digital health tools and telemedicine are also influencing vaccine delivery by enabling scheduling, adherence tracking, and remote monitoring. Taken together, these shifts create a dynamic playing field where scientific feasibility, regulatory clarity, patient-centered design, and distribution innovation intersect to accelerate the translation of oral vaccine concepts into practice.

Evaluation of how United States tariff measures enacted in 2025 have reshaped supply chain strategies, procurement dynamics, and manufacturing localization considerations

The cumulative impact of tariff policy changes enacted in the United States in 2025 has introduced a new set of considerations for vaccine developers, manufacturers, and procurement entities. These trade measures, while aimed at broader industrial strategy objectives, affect multiple nodes of the vaccine value chain, including the sourcing of active pharmaceutical ingredients, excipients, specialized packaging materials, and equipment used in fill-and-finish operations. As a consequence, organizations with globally distributed supply chains must reassess sourcing strategies and cost structures to mitigate exposure to increased import duties and procedural delays at ports.

In practical terms, the policy shift has accelerated conversations around supply chain localization, dual sourcing, and strategic stockpiling of critical inputs. Manufacturers are investigating nearshoring options and expanding relationships with domestic contract development and manufacturing organizations to reduce tariff-related vulnerabilities. These changes also influence contract negotiation dynamics with suppliers, where greater emphasis is placed on price transparency, freight optimization, and shared risk agreements. Procurement teams are increasingly modeling the downstream operational implications of tariffs, such as altered lead times and inventory turnover, to preserve continuity of supply for clinical programs and immunization campaigns.

For public purchasers and financing institutions, tariffs introduce complexities in budgeting and procurement timelines, prompting renewed interest in long-term supply agreements and incentivized manufacturing investments within tariff-favored jurisdictions. Importantly, the policy environment has encouraged cross-sector collaboration to balance national strategic goals with global health imperatives, including multilateral dialogues to ensure that tariff measures do not impede access to life-saving vaccines. Looking ahead, the industry is adapting through a combination of operational resilience measures, strategic partnerships, and targeted capital investments aimed at maintaining programmatic continuity while aligning with evolving trade realities.

Key segmentation insights integrating vaccine platform types, disease targets, demographic needs, and distribution channels to inform development and commercialization choices

Understanding the market requires a structured view across product, clinical, demographic, and distribution dimensions, each of which shapes development priorities and commercial approaches. Based on Vaccine Type, market analyses consider Conjugate Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, mRNA Vaccines, and Subunit Vaccines, recognizing that each platform presents distinct formulation challenges and immunological profiles for oral delivery. These differences influence decisions around antigen stability, dosing schedules, and the selection of protective excipients or delivery vehicles.

Based on Disease Indication, attention is given to key targets such as Influenza, Norovirus, Poliovirus, and Rotavirus, where oral delivery can offer strategic benefits in terms of mucosal immunity and population-level transmission interruption. The landscape for each indication varies by historical precedent, clinical endpoints, and regulatory expectations, affecting the pace and complexity of development programs. Based on Age Group, distinctions among Adult, Geriatric, and Pediatric populations underscore the need to tailor formulations, dosing strategies, and safety monitoring to physiological and immunological differences across the lifespan.

Finally, Based on Distribution Channel, routes to market such as Hospitals & Clinics, Online Pharmacy, and Pharmacies define the operational requirements for packaging, labeling, and cold chain management, as well as the patient engagement and adherence supports needed. Integrating these segmentation lenses reveals nuanced commercial pathways: certain vaccine types may align more naturally with mass campaign models and hospital-based distribution, while others could be optimized for retail pharmacy or direct-to-consumer channels. This layered segmentation informs prioritization for developers and commercial teams as they balance scientific feasibility with route-to-market realities.

Regional insights highlighting how Americas, Europe Middle East & Africa, and Asia-Pacific variations drive differentiated regulatory, manufacturing, and distribution strategies

Regional dynamics exert a profound influence on vaccine development priorities, regulatory interactions, and distribution models, necessitating a differentiated approach across global markets. In the Americas, public-private partnerships, advanced clinical trial infrastructure, and a mature commercial ecosystem often accelerate pathway clarity for novel delivery technologies, while regional manufacturing capacity and procurement frameworks shape decisions around localization and strategic alliances. Market adoption is also influenced by payer structures and programmatic priorities that vary between national immunization programs and private sector channels.

Europe, Middle East & Africa present a spectrum of regulatory environments and healthcare delivery models that require adaptive strategies. In some European markets, harmonized regulatory processes and strong pharmacovigilance systems facilitate lifecycle planning, whereas in certain Middle Eastern and African contexts, emphasis is placed on affordability, cold chain logistics, and integration with existing immunization schedules. Collaborative initiatives and donor-supported procurement remain critical levers to expand access in regions where infrastructure limitations challenge distribution of temperature-sensitive products.

Asia-Pacific demonstrates substantial heterogeneity, with advanced manufacturing hubs, strong biopharmaceutical innovation ecosystems, and high-capacity public health programs in some markets, juxtaposed with emerging markets where infrastructure investments are ongoing. Regional supply chains, translational science collaborations, and differences in disease burden inform clinical trial design and deployment strategies. These regional insights underscore the need for tailored regulatory engagement, manufacturing footprint decisions, and distribution partnerships that align with local priorities and operational realities.

Strategic company-level insights on how incumbent manufacturers, biotech innovators, CDMOs, and allied technology firms are shaping competitive trajectories in oral vaccines

Competitive dynamics in the oral vaccine domain reflect a mix of established vaccine manufacturers, specialized biotech innovators, contract development and manufacturing organizations, and formulation technology providers. Established manufacturers bring experience in scale-up, regulatory navigation, and large-scale distribution, positioning them to accelerate late-stage candidates toward broad deployment when technical challenges are resolved. Biotechnology firms and academic spinouts contribute disruptive platform technologies and early-stage science, particularly in areas such as mucosal immunology, oral mRNA delivery, and protective excipient systems.

Contract development and manufacturing organizations play an increasingly central role by offering technical expertise in specialized formulation, encapsulation, and fill-and-finish processes that are critical for oral product viability. Collaboration between platform owners and CDMOs often determines speed to clinic and commercial scalability. Additionally, companies focused on cold chain optimization, packaging innovation, and digital supply chain solutions are creating complementary capabilities that reduce logistical friction and improve adherence monitoring.

Strategic partnerships, licensing arrangements, and public-private collaborations are recurring motifs, enabling risk-sharing and leveraging of complementary strengths. Intellectual property strategies and platform modularity influence competitive differentiation, as does the ability to generate robust safety and immunogenicity data across diverse populations. For stakeholders evaluating partnership prospects or competitive positioning, the emphasis is on technological fit, regulatory experience, manufacturing scalability, and the capacity to address end-to-end delivery challenges.

Actionable recommendations for leaders to accelerate oral vaccine development through technology investment, regulatory engagement, supply chain diversification, and targeted commercialization

Industry leaders should adopt a proactive, multi-dimensional strategy to translate scientific promise into accessible oral vaccine solutions while managing commercial and geopolitical risks. First, invest in platform capabilities that address formulation stability and mucosal immunogenicity, including partnerships with formulation specialists and academic centers to accelerate preclinical learnings and de-risk clinical translation. Simultaneously, integrate regulatory strategy early by engaging with agencies to clarify evidence requirements for novel delivery routes, thereby shortening development timelines and reducing uncertainty.

Operationally, diversify supply chains to mitigate exposure to trade policy shifts and material bottlenecks. Establish strategic relationships with regional manufacturing partners and CDMOs to enable flexible production footprints and responsive scaling. On the commercial side, develop distribution models that align with target demographics and channels-hospitals and clinics for high-acuity programs, pharmacies for routine adult immunizations, and online pharmacy solutions to enhance access and adherence in digitally enabled markets. Complement these efforts with digital tools for patient education, scheduling, and post-market surveillance.

Finally, prioritize stakeholder engagement to build confidence among payers, public health authorities, and community leaders. Invest in robust real-world evidence generation and pharmacovigilance frameworks to demonstrate safety and effectiveness across age groups. By balancing scientific rigor, regulatory foresight, operational resilience, and targeted commercial execution, industry leaders can position their portfolios to capture the full potential of oral vaccine innovations.

Transparent research methodology combining expert primary interviews, literature synthesis, case study analysis, and data triangulation to ensure balanced and actionable insights

This research synthesis is underpinned by a rigorous methodology that integrates primary and secondary inputs to ensure robust, defensible conclusions. Primary research included structured interviews and consultations with subject-matter experts from vaccine development, clinical research, regulatory affairs, manufacturing operations, and public health procurement, providing practical insights into technical challenges and strategic priorities. These engagements were complemented by analysis of relevant peer-reviewed literature, clinical trial registries, regulatory guidance, and technical white papers to ground findings in contemporary science and policy.

Data synthesis employed cross-validation techniques to reconcile differing perspectives and triangulate conclusions, placing particular emphasis on reproducibility of clinical and operational observations. The study also reviewed anonymized case examples of process development and distribution implementations to extract transferable lessons and risk mitigation strategies. Quality assurance steps included expert review cycles, methodological transparency for key assumptions, and iterative refinement based on stakeholder feedback to enhance applicability across diverse organizational contexts.

Where appropriate, the methodology identified areas of uncertainty and recommended targeted research to address gaps, such as comparative immunogenicity studies across delivery platforms and operational pilots for alternative distribution channels. The approach balances depth and pragmatism to deliver insights that are both scientifically grounded and operationally actionable for decision-makers.

Conclusive synthesis emphasizing the promise of oral vaccines, residual scientific and operational challenges, and the need for coordinated industry and policy action

In conclusion, oral vaccines represent a strategic opportunity to broaden the toolkit for disease prevention by offering needle-free administration, potential improvements in mucosal immunity, and distribution efficiencies that align with contemporary public health priorities. Scientific and technological advances are progressively addressing historical barriers related to antigen stability and gastrointestinal delivery, while regulatory pathways are becoming more navigable through proactive engagement. Yet, challenges remain, including the need for robust safety and efficacy data across age cohorts, scalable manufacturing processes, and adaptive distribution models that handle variable infrastructure capacities.

External factors such as trade policy shifts and regional heterogeneity in healthcare delivery further complicate the pathway to broad adoption, underscoring the importance of resilient supply chain design and region-specific strategies. Industry players that combine platform innovation, strategic partnerships, and operational agility will be best positioned to translate oral vaccine potential into sustainable public health impact. Ultimately, success will require coordinated effort among developers, regulators, manufacturers, payers, and public health stakeholders to ensure that promising technologies are translated into accessible, safe, and effective interventions that meet the needs of diverse populations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing investment in probiotic-based oral vaccine formulations for enhanced mucosal immunity
  • 5.2. Regulatory approvals driving development of cold-chain-free oral vaccines in emerging markets
  • 5.3. Adoption of edible plant-based oral vaccines to reduce production costs and improve patient compliance
  • 5.4. Integration of nanotechnology carriers for targeted antigen delivery in oral vaccine platforms
  • 5.5. Expansion of oral polio vaccine eradication campaigns following strategic global partnerships and funding

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Vaccine Market, by Vaccine Type

  • 8.1. Conjugate Vaccines
  • 8.2. Inactivated Vaccines
  • 8.3. Live Attenuated Vaccines
  • 8.4. Mrna Vaccines
  • 8.5. Subunit Vaccines

9. Oral Vaccine Market, by Disease Indication

  • 9.1. Influenza
  • 9.2. Norovirus
  • 9.3. Poliovirus
  • 9.4. Rotavirus

10. Oral Vaccine Market, by Age Group

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Oral Vaccine Market, by Distribution Channel

  • 11.1. Hospitals & Clinics
  • 11.2. Online Pharmacy
  • 11.3. Pharmacies

12. Oral Vaccine Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Oral Vaccine Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Oral Vaccine Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. AstraZeneca plc
    • 15.3.2. Bharat Biotech International Limited
    • 15.3.3. Emergent BioSolutions Inc.
    • 15.3.4. GlaxoSmithKline plc
    • 15.3.5. Merck & Co., Inc.
    • 15.3.6. Moderna, Inc
    • 15.3.7. PT Bio Farma (Persero)
    • 15.3.8. Sanofi S.A.
    • 15.3.9. Sinovac Biotech Ltd
    • 15.3.10. Valneva SE

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ORAL VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ORAL VACCINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ORAL VACCINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ORAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ORAL VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ORAL VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ORAL VACCINE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ORAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ORAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ORAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORAL VACCINE MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ORAL VACCINE MARKET SIZE, BY MRNA VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORAL VACCINE MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ORAL VACCINE MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORAL VACCINE MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ORAL VACCINE MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL VACCINE MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ORAL VACCINE MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL VACCINE MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ORAL VACCINE MARKET SIZE, BY INFLUENZA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL VACCINE MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ORAL VACCINE MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL VACCINE MARKET SIZE, BY NOROVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ORAL VACCINE MARKET SIZE, BY NOROVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL VACCINE MARKET SIZE, BY NOROVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ORAL VACCINE MARKET SIZE, BY NOROVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL VACCINE MARKET SIZE, BY NOROVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ORAL VACCINE MARKET SIZE, BY NOROVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL VACCINE MARKET SIZE, BY POLIOVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ORAL VACCINE MARKET SIZE, BY POLIOVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL VACCINE MARKET SIZE, BY POLIOVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ORAL VACCINE MARKET SIZE, BY POLIOVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL VACCINE MARKET SIZE, BY POLIOVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ORAL VACCINE MARKET SIZE, BY POLIOVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL VACCINE MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ORAL VACCINE MARKET SIZE, BY ROTAVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL VACCINE MARKET SIZE, BY ROTAVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ORAL VACCINE MARKET SIZE, BY ROTAVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORAL VACCINE MARKET SIZE, BY ROTAVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ORAL VACCINE MARKET SIZE, BY ROTAVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORAL VACCINE MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ORAL VACCINE MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORAL VACCINE MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ORAL VACCINE MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORAL VACCINE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ORAL VACCINE MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORAL VACCINE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ORAL VACCINE MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORAL VACCINE MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ORAL VACCINE MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORAL VACCINE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ORAL VACCINE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORAL VACCINE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ORAL VACCINE MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORAL VACCINE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ORAL VACCINE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ORAL VACCINE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ORAL VACCINE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORAL VACCINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ORAL VACCINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ORAL VACCINE MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ORAL VACCINE MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ORAL VACCINE MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ORAL VACCINE MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ORAL VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ORAL VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ORAL VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ORAL VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ORAL VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ORAL VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ORAL VACCINE MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ORAL VACCINE MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ORAL VACCINE MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ORAL VACCINE MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ORAL VACCINE MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ORAL VACCINE MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ORAL VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ORAL VACCINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. AMERICAS ORAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS ORAL VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 107. AMERICAS ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 109. AMERICAS ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 120. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 130. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 134. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 160. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 164. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 165. AFRICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. AFRICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. AFRICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. AFRICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. AFRICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 170. AFRICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 171. AFRICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. AFRICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. AFRICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. AFRICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ORAL VACCINE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ORAL VACCINE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. ASEAN ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. ASEAN ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. ASEAN ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. ASEAN ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. ASEAN ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 192. ASEAN ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 193. ASEAN ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. ASEAN ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. ASEAN ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. ASEAN ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. GCC ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GCC ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GCC ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. GCC ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. GCC ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 202. GCC ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 203. GCC ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GCC ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GCC ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. GCC ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. BRICS ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. BRICS ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. BRICS ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. BRICS ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. BRICS ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 222. BRICS ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 223. BRICS ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. BRICS ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. BRICS ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. BRICS ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. G7 ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. G7 ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. G7 ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. G7 ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. G7 ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 232. G7 ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 233. G7 ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. G7 ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. G7 ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. G7 ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. NATO ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. NATO ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. NATO ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. NATO ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. NATO ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 242. NATO ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 243. NATO ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. NATO ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. NATO ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. NATO ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. UNITED STATES ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED STATES ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. UNITED STATES ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED STATES ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 253. UNITED STATES ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. UNITED STATES ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. UNITED STATES ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED STATES ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. CANADA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. CANADA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. CANADA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 260. CANADA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 261. CANADA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. CANADA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. CANADA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. CANADA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. MEXICO ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. MEXICO ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. MEXICO ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 268. MEXICO ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 269. MEXICO ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. MEXICO ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. MEXICO ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. MEXICO ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 273. BRAZIL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. BRAZIL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. BRAZIL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 276. BRAZIL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 277. BRAZIL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. BRAZIL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. BRAZIL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. BRAZIL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 284. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 285. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. GERMANY ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. GERMANY ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. GERMANY ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 292. GERMANY ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 293. GERMANY ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GERMANY ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GERMANY ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. GERMANY ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. FRANCE ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. FRANCE ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. FRANCE ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 300. FRANCE ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 301. FRANCE ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 302. FRANCE ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 303. FRANCE ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. FRANCE ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 305. RUSSIA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. RUSSIA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. RUSSIA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 308. RUSSIA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 309. RUSSIA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 310. RUSSIA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 311. RUSSIA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. RUSSIA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. ITALY ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. ITALY ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. ITALY ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 316. ITALY ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 317. ITALY ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 318. ITALY ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 319. ITALY ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 320. ITALY ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 321. SPAIN ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. SPAIN ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. SPAIN ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 324. SPAIN ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 325. SPAIN ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 326. SPAIN ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 327. SPAIN ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 328. SPAIN ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 329. CHINA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. CHINA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 331. CHINA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 332. CHINA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 333. CHINA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 334. CHINA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 335. CHINA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 336. CHINA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 337. INDIA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 338. INDIA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 339. INDIA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 340. INDIA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 341. INDIA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 342. INDIA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 343. INDIA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 344. INDIA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 345. JAPAN ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. JAPAN ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 347. JAPAN ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 348. JAPAN ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 349. JAPAN ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 350. JAPAN ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 351. JAPAN ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 352. JAPAN ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 353. AUSTRALIA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 354. AUSTRALIA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 355. AUSTRALIA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 356. AUSTRALIA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 357. AUSTRALIA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 358. AUSTRALIA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 359. AUSTRALIA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 360. AUSTRALIA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 361. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 362. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 363. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY DISEASE IND